Nagarajan Vijaiganesh, Tang W H Wilson
Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, OH, USA.
Congest Heart Fail. 2011 Jul-Aug;17(4):169-74. doi: 10.1111/j.1751-7133.2011.00244.x. Epub 2011 Jul 21.
Publications regarding the potential clinical utility of biomarker testing in the management of heart failure have been exponentially increasing over the last decade. The majority of non-cardiac biomarkers are commonly used to identify end-organ dysfunction or comorbidities. The diagnostic utility of natriuretic peptide testing has been well-established. Despite consistently demonstrating their prognostic values and some promising initial results, treatment guided by natriuretic peptide testing is still debated. Although cardiac troponins have been extensively used in diagnosis of myocardial injury, their primary use of biomarkers in advanced heart failure is prognostication and risk stratification. Congest Heart Fail. Congest Heart Fail. 2011;17:169-174. © 2011 Wiley Periodicals, Inc.
在过去十年中，关于生物标志物检测在心力衰竭管理中的潜在临床应用的出版物呈指数级增长。大多数非心脏生物标志物通常用于识别终末器官功能障碍或合并症。利钠肽检测的诊断效用已得到充分确立。尽管利钠肽检测一直显示出其预后价值和一些有前景的初步结果，但以利钠肽检测为指导的治疗仍存在争议。尽管心肌肌钙蛋白已广泛用于心肌损伤的诊断，但其在晚期心力衰竭中作为生物标志物的主要用途是预后评估和风险分层。《充血性心力衰竭》。《充血性心力衰竭》。2011年；17:169 - 174。©2011威利期刊公司。
